Related Experiment Videos
Allergen-loaded biodegradable poly(D,L-lactic-co-glycolic) acid nanoparticles down-regulate an ongoing Th2 response
I Schöll1, A Weissenböck, E Förster-Waldl
1Department of Pathophysiology, University of Vienna, Austria.
Summary
Biodegradable poly(lactic-co-glycolic) acid (PLGA) nanospheres effectively deliver birch pollen allergen Bet v 1. This allergen immunotherapy approach shows potential for few-shot treatment of type I allergies by modulating immune responses.
Area of Science:
- Immunology
- Biomaterials Science
- Allergy Research
Background:
- Biocompatible and biodegradable microparticles are increasingly utilized as antigen delivery systems.
- Poly(lactic-co-glycolic) acid (PLGA) nanospheres offer potential as allergen vehicles for type I allergy treatment.
Purpose of the Study:
- To investigate the efficacy of PLGA nanospheres as allergen vehicles for few-shot therapy of type I allergy.
- To evaluate the immune response to birch pollen allergen Bet v 1 encapsulated in PLGA nanospheres.
Main Methods:
- Encapsulation of Bet v 1 allergen into PLGA nanospheres (PLGA-Bet v 1).
- Assessment of antigenicity and immune response in a BALB/c mouse model.
- Evaluation of therapeutic potential through single-shot treatment of sensitized mice.
Main Results:
- PLGA encapsulation minimally affected Bet v 1 antigenicity.
- PLGA-Bet v 1 immunization induced allergen-specific IgG antibodies without hypersensitivity.
- Treatment with PLGA-Bet v 1 modulated Th2 responses, decreasing IgG1 and increasing IgG2a, IFN-gamma, and IL-10 production.
Conclusions:
- PLGA nanospheres effectively modulate ongoing Th2 responses in a mouse model of type I allergy.
- Data suggest PLGA nanospheres are suitable for formulating allergen extracts for few-shot immunotherapy.
- This approach holds promise for the treatment of type I allergies.